Characteristics of MDS patients
Patient no. . | Karyotype . | BM blasts, % . | Cytopenia . | IPSS . | WHO classification . |
|---|---|---|---|---|---|
| 1 | 46, XY | 1 | 1 | 0 | RA |
| 2 | 46, XX | 1 | 1 | 0 | RA |
| 3 | 46, XY | 2 | 1 | 0 | RA |
| 4 | 46, XY | 2 | 2 | 0.5 | RCMD |
| 5 | 46, XY | 3 | 3 | 0.5 | RCMD |
| 6 | 46, XY | 4 | 1 | 0 | RA |
| 7 | 46, XX | 5 | 3 | 1 | RAEB-1 |
| 8 | 46, XY | 6 | 2 | 1 | RAEB-1 |
| 9 | 46, XY | 7 | 3 | 1 | RAEB-1 |
| 10 | 46, XY | 8 | 2 | 1 | RAEB-1 |
| 11 | 46, XY | 9 | 3 | 1 | RAEB-1 |
| 12 | 46, XY | 11 | 2 | 2 | RAEB-2 |
| 13 | 46, XY | 11 | 2 | 2 | RAEB-2 |
| 14 | 46, XY | 11 | 2 | 2 | RAEB-2 |
| 15 | 46, XX | 12 | 2 | 2 | RAEB-2 |
| 16 | 46, XY | 15 | 2 | 2 | RAEB-2 |
| 17 | 46, XY | 16 | 2 | 2 | RAEB-2 |
| 18 | 46, XY | 19 | 1 | 1.5 | RAEB-2 |
| 19 | 46, XY | 19 | 2 | 2 | RAEB-2 |
| 20 | 46, XY | 19 | 3 | 2 | RAEB-2 |
| 21 | 46, XX | 27 | 2 | NA | MDS/AML |
| 22 | 47, XY, +8 | 0 | 2 | 1 | RCMD |
| 23 | 47, XY, +8 | 2 | 1 | 0.5 | RA |
| 24 | 47, XX, +8 | 2 | 2 | 1 | RCMD |
| 25 | 47, XY, +8 | 2 | 2 | 1 | RA |
| 26 | 47, XY, +8 | 4 | 0 | 0.5 | RA |
| 27 | 47, XX, +8 | 7 | 1 | 1 | RAEB-1 |
| 28 | 47, XX, +8 | 7 | 2 | 1.5 | RAEB-1 |
| 29 | 47, XY, +8 | 9 | 1 | 1 | RAEB-1 |
| 30 | 47, XY, +8 | 9 | 1 | 1 | RAEB-1 |
| 31 | 47, XX, +8 | 15 | 1 | 2 | RAEB-2 |
| 32 | 47, XX, +8 | 38 | 2 | NA | MDS/AML |
| 33 | 47, XX, +8 | 49 | 2 | NA | MDS/AML |
| 34 | 36, XY, del(5q) | 1 | 2 | 0.5 | 5q syndrome |
| 35 | 46, XX, del(5q) | 2 | 1 | 0 | 5q syndrome |
| 36 | 46, XX, del(5q) | 4 | 1 | 0 | 5q syndrome |
| 37 | 46, XX, del(5q) | 4 | 1 | 0 | 5q syndrome |
| 38 | 46, XX, del(5q) | 4 | 2 | 0.5 | 5q syndrome |
| 39 | 46, XX, del(5q) | 5 | 1 | 0.5 | RAEB-1 |
| 40 | 46, XY, del(5q) | 9 | 3 | 1 | RAEB-1 |
| 41 | 46, XX, del(5q) | 32 | 3 | NA | MDS/AML |
| 42 | 46, XX, del(5q) | 71 | 2 | NA | MDS/AML |
| 43 | 46, XX, del(20q) | 2 | 3 | 0.5 | RCMD |
| 44 | 46, XY, del(20q) | 4 | 1 | 0 | RA |
| 45 | 46, XX, del(20q) | 5 | 3 | 1 | RAEB-1 |
| 46 | 46, XY, del(20q) | 6 | 3 | 1 | RAEB-1 |
| 47 | 46, XX, del(20q) | 7 | 2 | 1 | RAEB-1 |
| 48 | 45, XY, –Y | 4 | 1 | 0 | RA |
| 49 | 45, XY, –19 | 42 | 2 | NA | MDS/AML |
| 50 | 45, XY, –7 | 2 | 1 | 1 | RA |
| 51 | 45, XX, –7 | 3 | 2 | 1.5 | RCMD |
| 52 | 45, XY, –7 | 8 | 0 | 1.5 | RAEB-1 |
| 53 | 45, XY, –7 | 14 | 3 | 3 | RAEB-2 |
| 54 | 45, XX, –7 | 19 | 2 | 3 | RAEB-2 |
| 55 | 45, XX, –7 | 48 | 1 | NA | MDS/AML |
| 56 | Complex | 17 | 2 | 3 | RAEB-2 |
| 57 | Complex | 19 | 3 | 3 | RAEB-2 |
Patient no. . | Karyotype . | BM blasts, % . | Cytopenia . | IPSS . | WHO classification . |
|---|---|---|---|---|---|
| 1 | 46, XY | 1 | 1 | 0 | RA |
| 2 | 46, XX | 1 | 1 | 0 | RA |
| 3 | 46, XY | 2 | 1 | 0 | RA |
| 4 | 46, XY | 2 | 2 | 0.5 | RCMD |
| 5 | 46, XY | 3 | 3 | 0.5 | RCMD |
| 6 | 46, XY | 4 | 1 | 0 | RA |
| 7 | 46, XX | 5 | 3 | 1 | RAEB-1 |
| 8 | 46, XY | 6 | 2 | 1 | RAEB-1 |
| 9 | 46, XY | 7 | 3 | 1 | RAEB-1 |
| 10 | 46, XY | 8 | 2 | 1 | RAEB-1 |
| 11 | 46, XY | 9 | 3 | 1 | RAEB-1 |
| 12 | 46, XY | 11 | 2 | 2 | RAEB-2 |
| 13 | 46, XY | 11 | 2 | 2 | RAEB-2 |
| 14 | 46, XY | 11 | 2 | 2 | RAEB-2 |
| 15 | 46, XX | 12 | 2 | 2 | RAEB-2 |
| 16 | 46, XY | 15 | 2 | 2 | RAEB-2 |
| 17 | 46, XY | 16 | 2 | 2 | RAEB-2 |
| 18 | 46, XY | 19 | 1 | 1.5 | RAEB-2 |
| 19 | 46, XY | 19 | 2 | 2 | RAEB-2 |
| 20 | 46, XY | 19 | 3 | 2 | RAEB-2 |
| 21 | 46, XX | 27 | 2 | NA | MDS/AML |
| 22 | 47, XY, +8 | 0 | 2 | 1 | RCMD |
| 23 | 47, XY, +8 | 2 | 1 | 0.5 | RA |
| 24 | 47, XX, +8 | 2 | 2 | 1 | RCMD |
| 25 | 47, XY, +8 | 2 | 2 | 1 | RA |
| 26 | 47, XY, +8 | 4 | 0 | 0.5 | RA |
| 27 | 47, XX, +8 | 7 | 1 | 1 | RAEB-1 |
| 28 | 47, XX, +8 | 7 | 2 | 1.5 | RAEB-1 |
| 29 | 47, XY, +8 | 9 | 1 | 1 | RAEB-1 |
| 30 | 47, XY, +8 | 9 | 1 | 1 | RAEB-1 |
| 31 | 47, XX, +8 | 15 | 1 | 2 | RAEB-2 |
| 32 | 47, XX, +8 | 38 | 2 | NA | MDS/AML |
| 33 | 47, XX, +8 | 49 | 2 | NA | MDS/AML |
| 34 | 36, XY, del(5q) | 1 | 2 | 0.5 | 5q syndrome |
| 35 | 46, XX, del(5q) | 2 | 1 | 0 | 5q syndrome |
| 36 | 46, XX, del(5q) | 4 | 1 | 0 | 5q syndrome |
| 37 | 46, XX, del(5q) | 4 | 1 | 0 | 5q syndrome |
| 38 | 46, XX, del(5q) | 4 | 2 | 0.5 | 5q syndrome |
| 39 | 46, XX, del(5q) | 5 | 1 | 0.5 | RAEB-1 |
| 40 | 46, XY, del(5q) | 9 | 3 | 1 | RAEB-1 |
| 41 | 46, XX, del(5q) | 32 | 3 | NA | MDS/AML |
| 42 | 46, XX, del(5q) | 71 | 2 | NA | MDS/AML |
| 43 | 46, XX, del(20q) | 2 | 3 | 0.5 | RCMD |
| 44 | 46, XY, del(20q) | 4 | 1 | 0 | RA |
| 45 | 46, XX, del(20q) | 5 | 3 | 1 | RAEB-1 |
| 46 | 46, XY, del(20q) | 6 | 3 | 1 | RAEB-1 |
| 47 | 46, XX, del(20q) | 7 | 2 | 1 | RAEB-1 |
| 48 | 45, XY, –Y | 4 | 1 | 0 | RA |
| 49 | 45, XY, –19 | 42 | 2 | NA | MDS/AML |
| 50 | 45, XY, –7 | 2 | 1 | 1 | RA |
| 51 | 45, XX, –7 | 3 | 2 | 1.5 | RCMD |
| 52 | 45, XY, –7 | 8 | 0 | 1.5 | RAEB-1 |
| 53 | 45, XY, –7 | 14 | 3 | 3 | RAEB-2 |
| 54 | 45, XX, –7 | 19 | 2 | 3 | RAEB-2 |
| 55 | 45, XX, –7 | 48 | 1 | NA | MDS/AML |
| 56 | Complex | 17 | 2 | 3 | RAEB-2 |
| 57 | Complex | 19 | 3 | 3 | RAEB-2 |
RA indicates refractory anemia; RCMD, refractory cytopenia with multilineage dysplasia; RAEB, refractory anemia with excess of blasts (5%-9% BM blasts RAEB-1, 10%-19% BM blasts RAEB-2); NA, not applicable; and 5q syndrome, MDS associated with isolated del(5q).